N-Deshydroxyethyl Dasatinib

TargetMol
Product Code: TAR-T18750
Supplier: TargetMol
CodeSizePrice
TAR-T18750-1mg1mg£138.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-5mg5mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-1mL1 mL * 10 mM (in DMSO)£252.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-10mg10mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-25mg25mg£507.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-50mg50mg£704.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-100mg100mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18750-500mg500mg£1,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
N-Deshydroxyethyl Dasatinib is a metabolite of Dasatinib, a dasatinib-based molecule that degrades ABL by binding to the IAP ligand via a linker to form SNIPER.N-Deshydroxyethyl Dasatinib is used in the study of cancer and immune diseases.
CAS:
910297-51-7
Molecular Weight:
443.95
Pathway:
Apoptosis|Metabolism|Others
Purity:
0.9596
SMILES:
O=C(NC=1C(Cl)=CC=CC1C)C=2SC(=NC2)NC3=NC(=NC(=C3)N4CCNCC4)C
Target:
Others|Drug Metabolite|IAP

References

Thappali SR, et al. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. Arzneimittelforschung. 2012;62(12):624-630. Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666.